Global Corticosteroid Eyedrops Market Size By Type (Cortisone, Dexamethasone), By Application (Adult, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Corticosteroid Eyedrops Market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.1 billion by 2031, growing at a CAGR of 7.1% during the forecast period (2023–2031). Corticosteroid eyedrops are widely used in the treatment of inflammatory eye conditions such as uveitis, allergic conjunctivitis, post-operative inflammation, and dry eye syndrome. The increasing prevalence of ocular disorders, growing geriatric population, and rising awareness regarding ophthalmic health are key factors driving market expansion. The surge in demand for minimally invasive therapies and expanding access to eye care services in developing countries are further fueling the market’s growth.

Drivers

1. Growing Prevalence of Eye Diseases:

An increase in the incidence of ocular inflammation, post-surgical eye complications, and autoimmune eye conditions is fueling demand for corticosteroid eyedrops globally.

2. Aging Population:

Elderly individuals are more susceptible to eye disorders requiring corticosteroid treatment. With the global population aging rapidly, this demographic shift is driving consistent market demand.

3. Technological Advancements in Drug Delivery:

Innovations in ophthalmic formulations, including preservative-free and sustained-release corticosteroid eyedrops, are improving efficacy and compliance, fostering market growth.

Restraints

1. Side Effects and Risk of Prolonged Use:

Potential adverse effects such as increased intraocular pressure, glaucoma, and cataracts from prolonged corticosteroid use pose challenges to market adoption.

2. Availability of Alternative Therapies:

The growing use of non-steroidal anti-inflammatory drugs (NSAIDs) and biologics for certain eye conditions may limit corticosteroid eyedrop usage.

Opportunity

1. Expansion in Emerging Markets:

Rapid improvements in healthcare infrastructure and increasing focus on eye care in regions like Asia-Pacific, Latin America, and the Middle East & Africa present significant growth opportunities.

2. Rise in Ophthalmic Surgeries:

The increasing number of cataract and refractive surgeries globally contributes to the growing demand for corticosteroid eyedrops in post-operative care.

Market by System Type Insights

Based on system type, the preservative-free corticosteroid eyedrops segment held the largest market share in 2023. These formulations are increasingly preferred due to their improved tolerability, especially for chronic use in sensitive eyes. The segment continues to expand as patients and clinicians favor options with fewer side effects and improved safety profiles.

Market by End-use Insights

In terms of end use, hospitals and ophthalmic clinics were the dominant end users in 2023. The availability of advanced diagnostic tools and expertise in these settings drives corticosteroid eyedrop prescriptions. However, the retail pharmacy segment is anticipated to witness strong growth, propelled by rising self-medication trends and over-the-counter availability in some regions.

Market by Regional Insights

North America led the corticosteroid eyedrops market in 2023, owing to high healthcare expenditure, robust ophthalmic infrastructure, and early adoption of advanced treatments. Meanwhile, the Asia-Pacific region is expected to exhibit the fastest growth rate during the forecast period due to increasing awareness, a large patient pool, and expanding eye care services across India, China, and Southeast Asia.

Competitive Scenario

Key players in the global corticosteroid eyedrops market include Allergan (AbbVie Inc.), Alcon Inc., Bausch + Lomb, Novartis AG, Sun Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., and Cipla Ltd. These companies are focusing on strategic mergers, product innovations, and geographic expansion. Notable developments include:

2023: Alcon launched a new preservative-free dexamethasone formulation in multiple European countries.

2024: Bausch + Lomb expanded its manufacturing facility to meet the growing demand for ophthalmic products.

2025: Sun Pharma partnered with a local distributor in Southeast Asia to expand its corticosteroid eyedrop portfolio regionally.

Scope of Work – Global Corticosteroid Eyedrops Market

Key Market Developments

March 2023: Allergan received FDA approval for a new formulation of loteprednol etabonate, designed for rapid relief in post-surgical inflammation.

June 2024: Novartis initiated Phase III trials for a novel corticosteroid eyedrop targeting autoimmune uveitis.

January 2025: Santen Pharmaceutical announced the acquisition of an ophthalmic drug manufacturer to expand its corticosteroid eyedrop capabilities in Europe.

FAQs

1) What is the current market size of the Global Corticosteroid Eyedrops Market?

The market size was valued at USD 1.2 billion in 2023.

2) What is the major growth driver of the Global Corticosteroid Eyedrops Market?

Key growth drivers include the increasing prevalence of inflammatory eye conditions and the expanding geriatric population.

3) Which is the largest region during the forecast period in the Global Corticosteroid Eyedrops Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to experience the fastest growth.

4) Which segment accounted for the largest market share in the Global Corticosteroid Eyedrops Market?

The preservative-free corticosteroid eyedrops segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Corticosteroid Eyedrops Market?

Major players include Allergan (AbbVie), Alcon, Bausch + Lomb, Novartis, Sun Pharma, Santen, and Cipla.